Moxham Christopher 4
4 · Fulcrum Therapeutics, Inc. · Filed Aug 12, 2021
Insider Transaction Report
Form 4
Moxham Christopher
Chief Scientific Officer
Transactions
- Sale
Common Stock
2021-08-10$17.00/sh−20,714$352,138→ 0 total - Sale
Common Stockm
2021-08-10$18.00/sh−31,071$559,278→ 0 total - Exercise/Conversion
Stock Option (right to buy)
2021-08-10−31,071→ 72,501 totalExercise: $7.84Exp: 2029-01-21→ Common Stock (31,071 underlying) - Exercise/Conversion
Common Stock
2021-08-10$7.84/sh+31,071$243,597→ 31,071 total - Exercise/Conversion
Stock Option (right to buy)
2021-08-10−20,714→ 103,572 totalExercise: $7.84Exp: 2029-01-21→ Common Stock (20,714 underlying) - Exercise/Conversion
Common Stock
2021-08-10$7.84/sh+20,714$162,398→ 20,714 total
Footnotes (3)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2020.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 28, 2021.
- [F3]The shares underlying the option are scheduled to vest 25% on the first anniversary of the vesting commencement date of January 22, 2020. The remainder of the shares underlying the grant shall vest in equal quarterly installments over the following three years until the fourth anniversary of the vesting commencement date, subject to continued service.